Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.

Trial Profile

Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms MILES-3
  • Most Recent Events

    • 14 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 06 Jun 2017 A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies (from Mar 2011 to Aug 2016, 531 patients) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 15 Jan 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top